You are here: Home :: Area NEM :: Medical science :: Human medicine

Maria Grazia Andreassi, Nicoletta Botto, Silvia Maffei

Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening

Keywords: genetic testing, hormonal replacement therapy, inherited thrombophilia, oral contraception, thrombotic risk

Venous thromboembolism is a well-known complication of oral contraception and hormonal replacement therapy. Inherited thrombophilia is viewed as an important determinant in modulating the effects of estrogens on thrombotic risk. An increasing number of kits for thrombophilic mutations [factor V Leiden, G20210A prothrombin and methylenetetrahydrofolate reductase (MTHFR) C677T genes] are becoming commercially available, and screening for inherited thrombotic risk is among the most requested genetic tests in molecular diagnostic laboratories. However, the question of routine genetic screening for thrombophilia before prescribing hormones is still a matter of debate. The purpose of this article is to discuss the usefulness and practical applications of thrombotic genetic testing to identify which women should be tested to improve both the safety and efficacy of individualized estrogen therapy.

Clinical Chemical Laboratory Medicine, Walter de Gruyter

Print ISSN: 1434-6621
Volume: 44, 05/2006
Pages: 514 - 521

Show full article (external site)

Show all available items of this journal

 

Area NEM